{"id":54792,"date":"2023-03-14T08:03:06","date_gmt":"2023-03-14T07:03:06","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/sensorion-announces-agenda-for-rd-day-showcasing-gene-therapy-for-inner-ear-disease\/"},"modified":"2023-03-14T08:03:06","modified_gmt":"2023-03-14T07:03:06","slug":"sensorion-announces-agenda-for-rd-day-showcasing-gene-therapy-for-inner-ear-disease","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/sensorion-announces-agenda-for-rd-day-showcasing-gene-therapy-for-inner-ear-disease\/","title":{"rendered":"Sensorion Announces Agenda For R&D Day Showcasing Gene Therapy For Inner Ear Disease"},"content":{"rendered":"
\n

\nThursday April 6, 2023, at 8am EDT, 2pm CEST\n<\/p>\n

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News:\n<\/p>\n

\nSensorion, (FR0012596468 \u2013 ALSEN) <\/b>a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the agenda for its R&D Day<\/b> on Thursday 6 April 2023, at 8am EDT (2 pm CEST).\n<\/p>\n

\nThe event will be held at the Hearing Institute (Institut de l\u2019Audition), an Institut Pasteur center, located at 63, rue de Charenton, 75012, Paris, France. A live webcast and a replay of the presentation will also be accessible.\n<\/p>\n

\nSensorion\u2019s management team, including CEO Nawal Ouzren, G\u00e9raldine Honnet, M.D., Chief Medical Officer, Laurent Desire, Ph.D., Head of Preclinical Development, and Christine Le Bec, Ph.D., Head of CMC Gene Therapy, will provide an update on the Company\u2019s development programs and expected milestones in 2023.\n<\/p>\n

\nKey Opinion Leaders (KOLs) from the field of hearing therapeutics will also give presentations related to patient needs, therapeutics and market landscape in key areas including hereditary monogenic forms of deafness,\n<\/p>\n

\nExternal speakers participating in this event include:\n<\/p>\n